Whitehawk Therapeutics (NASDAQ:WHWK) Stock Dropped to “Sell” by Wall Street Zen

Wall Street Zen lowered shares of Whitehawk Therapeutics (NASDAQ:WHWK – Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Several other research firms have also recently commented on WHWK. Stifel Nicolaus began coverage on shares of Whitehawk Therapeutics in a research report on Wednesday, September 30th. They issued a “buy” rating and a $9.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Wednesday, September 2nd. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $8.33.

Read Our Latest Research Report on WHWK

Whitehawk Therapeutics Stock Performance

WHWK stock traded down $0.01 during mid-day trading on Friday, hitting $3.06. 212,182 shares of the company were exchanged, compared to its average volume of 389,561. Whitehawk Therapeutics has a 1-year low of $1.97 and a 1-year high of $5.49. The firm’s 50 day simple moving average is $3.53 and its 200 day simple moving average is $3.84. The firm has a market cap of $180.57 million, a P/E ratio of -2.81 and a beta of 0.99.

Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01. On average, equities research analysts predict that Whitehawk Therapeutics will post -1.00 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Montanova Capital LLC increased its stake in Whitehawk Therapeutics by 16.2% in the 2nd quarter. Montanova Capital LLC now owns 4,300,000 shares of the company’s stock valued at $19,694,000 after buying an additional 600,000 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Whitehawk Therapeutics during the 2nd quarter worth about $8,807,000. ADAR1 Capital Management LLC bought a new position in shares of Whitehawk Therapeutics in the 2nd quarter valued at about $6,144,000. Eversept Partners LP grew its holdings in shares of Whitehawk Therapeutics by 17.9% in the 1st quarter. Eversept Partners LP now owns 306,800 shares of the company’s stock valued at $1,058,000 after acquiring an additional 46,541 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Whitehawk Therapeutics in the 2nd quarter valued at about $378,000. Institutional investors and hedge funds own 52.08% of the company’s stock.

About Whitehawk Therapeutics

(Get Free Report)

Whitehawk Therapeutics is a biopharmaceutical company focused on developing treatments for cancer. Its work centers on oncology drug research and development. Publicly available information provides limited detail about the company’s specific products, development programs, operating geographies, or leadership.

Further Reading

Analyst Recommendations for Whitehawk Therapeutics (NASDAQ:WHWK)

Receive News & Ratings for Whitehawk Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Whitehawk Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.